Foreword
Considerable investment is being made by the pharmaceutical industry to enable teams to work effectively together across departmental, functional, company and geographic boundaries. This is a natural response given the complex nature of an industry where key success factors include: When speed to market is critical, where informed and timely decisions can have large financial implications, collaboration is a key factor to ensure value is delivered.
Investment in collaboration has varied tremendously across companies in both the level of investment and the degree of success.
As a leading provider of collaborative solutions to the industry for many years, BT has developed a deep understanding of the particular collaboration issues faced by the pharmaceutical industry -and how they may be overcome to generate business improvements, improve cost management and deliver increased shareholder value. Active reviews with many of our customers have revealed different strategies in different stages of collaboration development.
We are acutely aware that the answer to improved collaboration lies in many areas such as corporate culture, social networks, and trust between individuals -to name but a few. Technology is a strong enabler to better collaboration but it must be intuitive, easy to use and enable natural people interaction for widespread adoption.
We also believe that the correct technology, coupled with cost reductions, can allow richer social collaboration and more intuitive usability. These factors include, but are not limited to: It is against this background that BT commissioned this research to develop winning strategies for collaboration … and to share them with all interested parties.
We are sure that you will find this report a valuable aid to improving your collaboration initiatives.
Gary Hawksworth, Healthcare Solutions, BT
Executive Summary
In an environment of rising costs and increasing demands on productivity and innovation, the challenge for today's pharmaceutical company is to "do more with less." Having sought economies of scale and product pipeline boosts through M&A activity, pharmaceutical companies are being forced to look internally to seek the improvements needed to meet the expectations of financial investors. Productivity gains at each phase, however small, have an amplifying effect -"they don't just add up, they multiply." Enterprises that fail to use modern communication technologies and who do not leverage the knowledge base of their workers, limit the potential for collaboration and run the very real risk of falling behind the competition.
Collaborative solutions employ information systems to enable individuals or groups of individuals to work concurrently on information. The result is that the working environment behaves in the same way regardless of geographical location, communication channel or device -and the benefits apply to all:
• Advanced interaction
• Collaborative working
• Mobility
We are in the midst of a fundamental paradigm shift as new technologies bring integrated voice, video, and web solutions to the pharmaceutical desktop. Emerging collaborative solutions now offer the user the ability to co-ordinate seamlessly between tools without the need to switch between systems. Information can be shared in an integrated and synchronised manner allowing decisions to be made on the most up-to-date information.
Collaborative solutions provide both hard, quantifiable benefits and many soft, difficult to measure benefits. Even small productivity increases can shave months off development times and provide millions of dollars in savings; while the soft benefits such as improved management of dispersed teams and faster decision making, accrue to deliver significant productivity improvements.
Study findings highlighted the fact that collaboration is primarily about behaviour not technology. Successful implementation of collaborative working practice and collaborative tools requires:
• A corporate culture of openness and sharing Although all pharmaceutical companies practice collaborative working, the quality in many cases is poor and leaves significant room for improvement.
This report examines the relationship between the key elements of technology and behaviour, and provides an insight into the winning strategies for further improvements in business performance through enhanced collaborative practice in the pharmaceutical industry.
Study Objective
The objective of this project was to review how well collaborative practice is embedded in today's pharmaceutical industry by understanding the relationship between business performance, business processes and collaborative behaviour. The project focused on the use of tools in normal working practice and their relation to the culture and behaviour within the organisation.
The study was based on 30 semi-structured, qualitative, in-depth interviews conducted with a representative sample of executives from a wide range of functional areas including discovery, clinical development and commercial.
Interview feedback was used to build an overall picture of the macrobusiness processes which might benefit from improved collaborative working. 
The Industry Faces Profound Challenges
Today's pharmaceutical industry exists in a fast-changing environment, with mounting pressures exerted from many different directions including regulatory constraints, rising costs, demands on productivity and innovation, mergers and challenges to patent protection.
Drug development costs are reaching unsustainable levels -in 2003, in excess of $900 million was required to take a product to market, as opposed to $230 million in 1987. 1 Blockbusters, which have driven impressive growth in recent years, are becoming increasingly difficult to find and the falling number of new medicines now means that R&D productivity is a key issue. Just to keep pace with the annual industry growth rate of 10%, the top 10 Pharma players need to launch at least 5 significant NCEs per year. 2 Companies have invested heavily in new discovery technologies characterised by the convergence of life sciences and information technology. We are now entering a period where the promise of these "New Sciences" will begin to deliver, but the application of new technology has created an added problem in terms of the vast amounts of new data that now need to be organised and managed.
Added to these factors are increasing regulatory demands and the need to demonstrate the utility of new treatments versus existing treatments.
Recent concern about the safety of medicines in addition to the shrinking willingness of the public to accept side effects, has led to some drug-safety experts and lawmakers wanting even larger and longer clinical trials for new drugs, further increasing development costs.
The research-based pharmaceutical industry has long been one of the most complex and resource-intensive in the world -but complexity is now increasing at a spectacular rate. In order to maximise the quality and speed of the discovery and development process, companies are dramatically increasing the collaborations within the different parts of R&D as well as their reliance on external partners. This collaborative approach is the right way to do business, but it adds a level of complexity to both intra-and interfunctional interactions. Multiple units within an organisation must collaborate across the extended enterprise i.e. not only with each other, but also with external partners.
Exacerbating these complexities is the challenge of size. Consolidation within the industry as well as organic growth, have created extremely large, global organisations. Infrastructures are stretched to the limits, 'Collaboration has been a huge successgeographically dispersed teams recognised the need for a vehicle of communication over and above telephone and travel.' inefficiencies are amplified and simple tasks such as access to data, become cumbersome. Paradoxically, these very large organisations still rely on high-innovation work and intensive small group collaboration.
Science innovation occurs best in smaller environments. A serious and growing challenge is therefore for companies to re-create a small-company environment within the larger organisation without harbouring "knowledge silos."
The result of these challenges is that the pharmaceutical industry now has to do "more with less," the response will require a fundamental change in the traditional way companies operate internally; without this, increased innovation -and increased profitability -is an improbable outcome.
The Importance of Collaboration

What is Collaboration?
The definition of collaborative working varies greatly from person to person and from company to company, in its simplest form, secure collaborative working uses information systems to enable individuals or groups of individuals to work concurrently on information, no matter whether they are dispersed or co-located.
Collaboration is already a huge part of the corporate way of life in the pharmaceutical industry -employees rely on email, telephone and video conferencing; they are also leveraging the capabilities of the digital workplace to share knowledge and information with people across the enterprise as well as with external networks. However, in reality not all pharmaceutical companies have realised the true potential of collaborative tools -much money has been spent in this area but crucially many companies have omitted to invest in encouraging personal interaction, the result being poor uptake and severe limitations on true collaborative working.
To derive value from collaborative investments, collaboration must be viewed as more than just technology deployment. This activity is about behaviour, work habits, culture, leadership, management, and business goals and value. Collaboration is a business strategy, not a tool strategy and technology implementation alone does not change behaviour.
Collaboration strategies are now shifting from a focus on tools to the integration of collaboration into business processes to improve performance. Improving work practices within business processes requires collaboration "in context" while tapping into 'communities of practice' as sources of best practice and innovation. "Contextual collaboration" as it is known, has the potential to help pharmaceutical companies bridge the gaps that chronically reduce productivity such as the geographic dispersal of workers, the coordination of management where there is joint responsibility, and working across organisational boundaries and time zones. The goal is to make online collaboration as simple and as intuitive as it is to work with people in the same room; while extending the boundaries of that "room" to be independent of function or geographic location.
The Need for Collaboration
Given the pressures that the pharmaceutical industry currently faces, it is clear that even incremental gains in efficiency and productivity can result in a faster time to market for a product or technology. As part of this strategy many companies are putting in place initiatives to improve collaboration across the extended enterprise. The primary purposes are to foster communication between increasingly specialised and geographically dispersed groups, provide accurate reports of programme advancement, and support decision making processes. The success of any business is driven largely by the quality of decision making and the skill at which teams execute those decisions. Both decision making and decision execution are dependent on the quality of communications and access to information and knowledge. Better communications and knowledge access lead to better decisions, and better results implementing those decisions.
Productivity gains at each phase, however small, have an amplifying effect -they don't just add up, they multiply. Enterprises that fail to use modern communication technologies and who do not leverage the knowledge base of their workers, limit the potential for collaboration and run the very real risk of falling behind the competition.
Knowledge Collaboration
The pharmaceutical industry is unique -essentially pharmacos and biotechs collect and manage knowledge, the drug products being the physical manifestation of this process.
Knowledge is said to exist in two forms: 3 a. Knowledge which can be expressed in words and numbers. This is known as "explicit" knowledge and can be easily communicated and shared in the form of data, standard procedures or universal principles. This is the hard knowledge stored in databases. b. Knowledge stored in people's heads. This is known as "tacit" knowledge and is highly personal and hard to formalise. Insights, experience, intuitions and hunches fall into this category.
In a strict sense, it is the individuals themselves that work within the pharmaceutical industry that create knowledge -this can occur in one of four ways: a. Socialisation -formal and/or informal discussions as well as corridor chats leads to the sharing of opinions, observations and knowledge. Participants are sharing their "tacit" knowledge.
b. Externalisation -this is where an individual converts the knowledge from his/her own head into a format which can be reused by other people -e.g. by writing a report or summing up experimental conclusions. Here "tacit" knowledge is being converted into an "explicit" form.
c. Combination -here individuals take "explicit" knowledge (or data) from one or more sources and combine them to form new knowledge. This is the combination of existing "explicit" knowledge -e.g. an individual may mine a database and publish his findings for others to use. d. Internalisation -this is where an individual uses "explicit" knowledge to create new "tacit" knowledge in his/her own head -e.g. equivalent to the above example of mining the database but not publishing the results.
The knowledge-intensive nature of pharmaceutical R&D makes the ability to capture, communicate and exploit knowledge, not merely to provide decision-support tools, a key determinant of their success. Systems are already available to take care of explicit knowledge -SOPs and other procedures as well as clinical data can be managed through intranets, document management systems and information management systems.
The hard part is managing the tacit knowledge -e.g. tapping into the experience, intuition, and knowledge in a scientist's head. This type of knowledge is almost impossible to document and according to many respondents, represents a huge problem for any organisation. Important tacit knowledge is too often lost through staff turnover.
Conversion between tacit and explicit knowledge requires the interaction of human beings and is instrumental in the formation of new knowledge.
Collaborative tools play a large part in this process by facilitating the human linkages -whether by means of a directory of different thought leaders in a given company or by virtual meetings that bring subject matter Collaborative tools underpin the processes of knowledge creation in the pharmaceutical industry -without effective collaboration the products of R&D cannot be realised -i.e. knowledge cannot be created without facilitating human linkages, and documents cannot be produced unless geographically dispersed teams are united.
The Global Enterprise
All the companies interviewed work in a collaborative way utilising teams to progress individual projects which are aggregated into drug discovery, candidate development and launch programmes. Work is sub-divided down from large programmes into projects and sub-projects to which teams of specialists deliver their outputs.
The cross-functional team is the basic functional unit and consists of a core group which is supported by an extended network of specialists. Work is allocated across the team members for concurrent completion.
Individuals and teams are constantly connecting with one other, allowing them to share information and knowledge in order to progress projects forward. However, the effectiveness of the collaborative working practices employed by functions, teams, and individuals varies greatly -both by company and within individual companies.
The nature of the project work and the resultant collaborative working style varies depending on the area of R&D.
In discovery, data collaboration predominates. Researchers share and explore new ideas, collect and record data and synthesise it to validate these ideas and create new knowledge. Higher teams must then collaborate across functions to evaluate this information to decide on future research directions. Typical discovery cross-functional teams include: 
Cross-Functional Teams are the Norm
All respondents reported that team working has become the predominant way of working at all levels. Individual working now may only account for less than 40% of daily working time compared to historic norms. The trend is to continue to work more in teams and undertake more joint work together with colleagues during meetings.
Teams have also become much more dynamic and may be formed on an ad hoc basis to meet short-term needs, or on a long-term basis to meet strategic objectives. Tactical teams rely on accessing information quickly and establishing short-term collaborative relationship to solve a specific tactical problem or manage a particular study. After the work is completed in weeks or months, they break-up and individuals are reassigned to new teams. It is increasingly common for functional specialists to be working both tactically and strategically on several different teams concurrently.
In contrast, at the start of a new candidate development programme a "product team or therapeutic team" is appointed. These long-term teams are responsible for steering the development programme through to launch. The team is responsible for apportioning and delegating tasks/subprojects to functional departments. Therefore, team members have to establish a wide network of collaborative partnerships with the various specialist functions -usually spanning several different international sites.
Functional departments in development are now largely repositories for knowledge and resources to service the needs of the therapeutic areas. In the majority of companies interviewed, therapeutic areas are discrete with little cross therapeutic communication and collaboration, albeit with a few notable exceptions driven by "grass roots" scientists. The result is "therapeutic silos," especially in clinical where there is a marked resistance for therapeutic teams to share good and bad experiences with other teams.
This issue of "lessons learned" is being addressed by a few companies to spread "best practice" and reduce repeatable and avoidable mistakes made by project teams.
Study results confirmed that the cross-functional team is now the cornerstone of all team working in the industry and is prevalent at all levels.
Cross-functional teams are not simply site specific but are, more often than not, international in their dimensions. The variety, structure and duration of these cross-functional teams will continue to increase.
The Move to Virtual Teams
Project working has changed significantly in the pharmaceutical industry as companies have become increasingly decentralised. Organising and tracking project work could easily be done in the past by moving around on site to see all team members -individuals could simply exchange information and brainstorm together in the same room. Now with team members highly distributed, managers have to visit project resources virtually rather than physically -this is virtual project management. Project working and management is increasingly using Internet -based collaboration tools.
A virtual project is a collaborative effort towards a specific goal or accomplishment which is based on "collective yet remote performance." 4 This need to work apart and together has driven the need for management tools that enable communication and coordination at a distance. The global structure of teams has grown up to support the "virtual projects / programmes" that now dominate the way R&D is progressed on a worldwide scale. This trend to web project management has facilitated distributed decision making in global teams, the next step being integrated process management. 
Managing Global Diversity
The research indicated a clear trend for companies, who although global, favoured as much co-location for discovery team members as possible. In development, a minority of respondents reported a trend to regionalisation.
Pre-launch to commercialisation was very much driven by global teams.
In discovery, intensive collaboration is crucial to enable the core teams to exchange information and validate information on drug targets and leads.
Study findings suggested that this is best undertaken in an environment where scientists can easily physically share information on their areas faceto-face and informally. The research clearly indicated an emerging trend towards co-location which was felt to enhance collaboration and knowledge sharing between teams by reinforcing social networks. Discovery units tend to be grouped together by a therapy speciality on specific sites to foster the feeling of being part of a small company and of entrepreneurship -yet with the resources and support of a global player. Clinical development has become more complex with higher standards and with larger, more global trials. Product and study teams have become international with representatives from different countries and cultural backgrounds working together to manage projects on a virtual basis.
Overlaid on this has been the M&A activity which respondents indicated had often brought different or even conflicting working practices and hindered collaboration. The research clearly indicated that the majority of companies contacted were struggling to efficiently and effectively manage the complexity of global clinical development in a collaborative manner.
The key strategic team in development/pre-launch has become the "global product team or therapeutic team" -a high level and powerful crossfunctional team which is responsible for managing the whole development programme from the time a lead becomes a candidate though to launch where it will hand over to the global commercial/marketing team. Typically this team will comprise of representatives from key clinical departments as well as commercial (strategic marketing).
Top management has invested very significant decision making power in this team which in the past would have rested with functional heads and technical specialists. However, respondents have indicated that this has caused collaboration problems due to an emphasis on individual task completion rather than collective thinking -i.e. each team member is so focused on his/her own share of the work that they lose sight of the common objective.
Outsourcing and working with external suppliers has become an every day activity for R&D teams. No more so than for clinical teams who have an ever increasing need to collaborate closely with CROs and contract laboratories; however, the depth and breadth of this collaboration is in the majority of cases limited. There is significant resistance to allowing the CRO or laboratory team members to work closely with the core study or product teams. Respondents were unanimously suspicious of contractors and were reluctant to share information and knowledge with them. In part respondents commented that the strategic goals and aims of CROs were not aligned to that of their customers.
Room for Improvement in Pharmaceutical Companies
Although all pharmaceutical companies practice collaborative working, the quality in many cases is poor and leaves significant room for improvement. This is because companies have had to manage a new and more complex environment in which their R&D and commercial teams are widely dispersed -due to both M&A activity and organic growth.
The research showed that team members do not fully commit themselves to collaboration and fail to achieve the "multiplier effect" of true collaborative working -instead they simply tolerate collaboration, not getting much more out of it than they commit to it. There was a growing realisation amongst some respondents that simply putting together a There was a consensus from the research that effective and timely communication practices are the basis of collaborative working. The majority of respondents wanted to have at least one face-to-face meeting with other team members prior to the commencement of a project. This very human need has been lost as a result of decentralisation. Repeated reorganisations have broken up many social networks and with so many people spread over so many locations, it is very difficult to re-establish these social links. E-tools from a team working perspective, so far have not managed to effectively recreate and rebuild these social networks for effective team working.
The respondents also reported that the old ways of disseminating information between team members and their "extended networks" do not work efficiently anymore. The pressure to meet deadlines especially in development has meant a lack of time for proper exposure and testing of 'In the long-run if employees don't evolve, then they won't last!' knowledge. Similarly the lack of opportunities to access people either because they are in meetings or simply not in the office due to travel commitments or home working, limits opportunities for knowledge sharing and collaboration. The reluctance of product teams to seek external knowledge through closer collaboration with functional departments and to exercise "best practice" across therapeutic areas has led to some significant problems -including avoidable delays and even major safety
concerns. This appears to be in part due to the emasculation of functional departments and the intense pressure on product teams to avoid delays to project schedules.
The system-centric company
In Practice • High investment in sophisticated tools but slanted strongly towards improving discovery productivity and efficiency. Slow to introduce collaborative tools for the rest of the company.
• Indiscriminate and over use of e-mail: -mass emailing for corporate communications -"block deletes" without reading -emails often need to be backed up by voice calls to ensure receipt • "Metrics" orientated environment deters workers from entering information readily into the official system -regarded as too "reports" orientated to be a true database.
• High resistance to change. Scientists reluctant to share "personal lab information" by switching from paper to e-lab notebooks.
• Restricted access to "expertise locator" available to higher management only -e.g. team leaders and upwards. • Shared workspaces used to varying degrees and success -many just "data dumps." Preference to share data via email attachments.
• No official top management encouragement towards information sharing or collaboration -simply viewed as just "another management initiative." • High preference for insular, small teams with little interest in collaborative working with other teams. • Social networks predominate. • Teleconferences and net meetings main meeting tools for virtual teams.
• Limited use of videoconferencing due to poor quality images.
In Theory
• Company intranet in place.
• Advanced system in place for tracking the efficiency of the discovery process -for example:
-therapy areas under investigation at any one time -number of employees working on a particular area, and -status of target evaluation • A sophisticated discovery portal system that allows users to define and receive information that interests them -e.g. a biologist's page will be different to that of a chemist's even though at times the same information is being mined.
• Users are able to submit news onto the system and make it available to others in different locations.
• Planned investment in technology to collect lab bench information e.g. e-lab notebooks.
• Portal system to be rolled out over the whole company.
Company A: has invested much money in collaborative technologies and in-house software development but has failed to pay attention to the "human issues" surrounding technology implementation. Behaviour has not widely changed as a result of implementation and resistance to change persists.
In Practice
• High investment in sophisticated tools but slanted strongly towards improving discovery productivity and efficiency. Slow to introduce collaborative tools for the rest of the company. • Indiscriminate and over use of e-mail:
-mass emailing for corporate communications -"block deletes" without reading -emails often need to be backed up by voice calls to ensure receipt • "Metrics" orientated environment deters workers from entering information readily into the official system -regarded as too "reports" orientated to be a true database.
In Theory
The culture conflict company
In Practice
• The new merged organisation has stepped back 3-4 years in terms of collaborative efforts compared to the strong predecessor company.
• Collaborative efforts have ceased until the new organisation reaches a steady-state -losing valuable time.
• Incompatible legacy data in many different formats.
• Significant "tacit" knowledge lost as a result of staff turnover following merger -failure to manage this in the transition period.
• There has been a failure to nurture "communities of practice"-a "kick start" will be required to recreate them and build new relationships.
• The concept of a shared workspace differs in each predecessor company. This imbalance has led to the inappropriate and over-use of email in certain situations.
• Teleconferencing and email attachments predominate in the new organisation with limited use of share workspaces and videoconferencing.
• An inherent dislike of sharing information has been compounded following merger with the arrival of many new, unfamiliar and unknown people from a different company. Internal silos persist especially along company boundaries.
• An efficient "expertise locator" remains an unmet need -but top management do not want to invest in this area. Many workers still rely on their social networks and self-developed contact lists; but networks have been broken following merger.
• In the new organisation there is a need for more customised information -too much is pushed at workers via email and it takes too long to find operationally relevant data.
In Theory
The collaboratively strong predecessor company: • Organised its knowledge management and collaborative efforts around the intranet and a Groupware model: -All tools were accommodated on the intranet -Single point of entry was provided via portal technology -The central data repository had forced people to store information in a standardised format -"future proofing" -Communities of interest were very active -Videoconferencing was a readily available tool • Had strong commitment to using collaborative working practices from top management.
• Had widespread commitment to the use of cross-therapeutic collaborative teams to bring "learning" from across the organisation.
The collaboratively weak predecessor company:
• Termed "weak" as a result of its corporate culture towards collaboration and poor implementation of collaborative working practices.
• It had many of the same e-tools for collaborative working as the strong company, but simply viewed e-tools as an "added layer of complexity to the business, rather than "an opportunity to improve productivity and effectiveness."
• Knowledge management was not a corporate priority and there were limited initiatives in place.
Company B: the collaboratively weak company purchases the collaboratively strong company and collaborative efforts grind to a halt following merger.
In Practice
In Theory
The collaboratively strong predecessor company:
• Organised its knowledge management and collaborative efforts around the intranet and a Groupware model: -All tools were accommodated on the intranet -Single point of entry was provided via portal technology -The central data repository had forced people to store information in a standardised format -"future proofing" -Communities of interest were very active -Videoconferencing was a readily available tool • Had strong commitment to using collaborative working practices from top management.
The collaboratively weak predecessor company:
Company B: the collaboratively weak company purchases the collaboratively strong company and collaborative efforts grind to a halt following merger.
'Culture is the single biggest barrier to sharing knowledge and information.' 'There are no real incentives to promote information and knowledge sharing.'
The collaborative company
In Practice
• 'Grass roots' scientists within these tight therapeutic areas recognised the benefits of collaboration and requested the formation of communities of practice to link people across the organisation around a given subject.
• The majority of communities of practice are supported by adequate resources.
• Workflow benefits are increasingly being realised as a result of access to e-tools via the desktop.
• Increased use of mobile systems for remote workers -especially senior executives and remote/home office workers.
• Cross-therapy learning events take place in order to generate new knowledge and re-use existing knowledge.
• Adoption and use of the e-collaborative tools remain patchy throughout the organisation despite intensive support efforts.
• The concept of a shared workspace differs in each predecessor company. As in other companies, this imbalance has led to the inappropriate and over-use of email in certain situations.
• To reduce the amount of "corporate emails" the onus has now been place on individuals to check the relevant bulletin boards.
• Increased emphasis on visual communications: -High quality videoconferencing available (as good as faceto-face) but very expensive and available only on major sites -Access problems to normal video suites -Evaluating video kiosks in offices and labs for "impulse use"
In Theory • Discovery efforts in the new organisation were organised into tight therapeutic areas to allow smaller groups of researchers to work independently and quickly (recreating a small company environment).
• Branded collaborative intranet.
• Communities of practice in place company-wide via portal technology.
• Central data repositories.
• Implementation of e-lab notebooks in the near future to enhance discovery data sharing and collection.
• Expertise bank.
• Groupware software in place: Company C: following merger a few years back, this company has cautiously and carefully invested in the etools as well as in change management to help workers adapt and adopt new working practices. This system has been built around communication and collaboration rather than knowledge management.
Ignore Cultural Issues at your Peril
The biggest challenge to get employees to work together collaboratively is not a technological problem -it's a cultural and organisational one. 5
The study identified a number barriers to collaborative working which include:
• Inherent dislike of sharing information -"knowledge is power"
• Low perceived "value" in sharing information As companies grow and as the amount of information generated increases, fewer people have time to read the literature or are able to personally interact with those outside their particular programme. This results in isolated projects, the inability to stay current, and the repetition of effort.
The problem in large pharmaceutical companies is that there are too many people, too much information and too little time devoted to overcoming the barriers to sharing information in order to develop a collaborative culture.
Collaborative tools on the market today make it easy to coordinate large groups by enabling members to post questions, work jointly on documents, schedule meetings and track progress toward goals. But not every company is positioned to take advantage of the tools. The danger for many is overspending on collaborative technologies without making the cultural and organizational adjustments necessary to derive any benefit from them.
Collaboration software just won't work if you don't have an environment that encourages people to work together. This will be a big leap for many companies where individuals are rewarded for controlling knowledge and highlighting their own achievements, rather than for sharing knowledge and focusing on team accomplishments.
The study results highlighted that culture was indeed a critical factor in ensuring greater collaboration -"as with any technology implementation, 20% rests on the technology itself, and 80% on culture." This issue is even more important where 'virtual teams' are concerned -the process of developing a common understanding in virtual teams is complex and often slows decision making down. Many respondents felt frustrated by their company's internal culture as it does not create the right environment for collaboration.
The importance of Relationships for Effective Collaboration
Many times in the context of this research respondents have commented that nothing quite beats face-to-face meetings -i.e. "seeing the whites of their eyes." To work effectively, relationships must be built with other team members or decision makers; and close relationship are best built through face-to-face contact. collaboration becomes difficult as individuals have to work around managerial "egos" and sensitivities.
Information hoarders will always exist and with a lack of incentives that reward results, personnel often feel that it is not in their interests to share information -they become economical with information, thus impeding collaborative efforts.
In many cases collaboration is at odds with the company's corporate culture so implementation will be disruptive. Shifting a corporate culture from being competitive to being co-operative is not easy, requiring changes at all levels of the organization, including the CEO.
The Formation of the 24/7 Culture
With businesses becoming global and with the vast majority of pharmaceutical companies having offices across all time zones, it is often necessary to conduct business outside the normal working day. The time differences between the US and Central Europe, or between Europe and Asia only allow for minimal work day overlap. This requires interaction between global team members to occur early in the morning or late into the evening and team members that engage in frequent global interactions might keep a 12-16 hour a day work schedule. This type of frequent, out-ofhours interaction has a negative impact on quality of life.
Language Barriers Impede Collaboration
Collaborative teams within pharmaceutical companies are more than likely to include many different nationalities, particularly in the strategic prelaunch teams which are global by nature. As more and more collaboration is becoming virtual and thus not face-to-face, team members often forget that English may not be their colleagues' first language. Very often people are guilty of not making allowances for others, particularly when there is little face-to-face contact. Silences can be misinterpreted as a failure to understand and even as stupidity when in fact, they are due to colleagues taking the time to work out a response.
Organisational Framework for Collaboration
Organisational structural changes during the 1990s as a result of M&A activity and efforts to speed up development had far reaching changes on teams and team working. One of the key changes was to structure aspects of discovery and all development around therapeutic areas, rather than functional departments. In the new structures respondents explained that functional departments are required to "sell their services" to therapy areas and sometimes to compete with external providers e.g. CROs, as top IT departments of many large pharmaceutical companies appear to be out of touch with the real needs of the business and often lag significantly behind the pace of technological change. However, some respondents mentioned that IT departments are now catching up and focusing more on business needs.
The Backbone for Collaboration
Pharmaceutical companies are organising their collaborative technology platforms around an intranet and Groupware model. 
Intranet
An intranet permits a widely dispersed group of people to interact, connecting them and their ideas. It offers the best and fastest solution for information to be dispersed in order for knowledge to be created but it cannot succeed alone.
The goals behind a collaborative intranet include:
• Knowledge cannot be separated from the communities that create, use and maintain it. These communities are particularly useful in the pharmaceutical industry with an organisational structure that tends to be based on crossfunctional teams. Communities of practice are effective tools to link people within their discipline while maintaining the focus of a cross-functional team. Industry experience is that behavioural and organisational, rather than technology issues need to be in the centre of attention when establishing new or encouraging existing communities of practice. A critical requirement is resource allocation to help create and maintain a viable community -information and links must up-to-date, without this information flow will stagnate and the community will die. 
Groupware
Groupware is software that groups or teams use together over computer networks and the Internet. It is based on the assumption that computer networks can help people increase their decision making ability and productivity by collaborating and sharing information. The core element of Groupware is that it provides mechanisms to share and distribute information. Frequently, communication is informal in this environment and users freely exchange information and collaborate. Groupware technologies are particularly well suited to R&D, where specialists in given technologies or techniques who may be dispersed worldwide need to exchange their expertise in order to find solutions to specific problems.
Groupware defines the flow of documents and the work that must be done to complete the project. It facilitates interaction which must occur in order for knowledge to be created and decisions to be made by providing communication and collaboration mechanisms where face-to-face conversation is difficult or expensive.
Some Groupware systems offer simple communication tools such as email, instant messaging, white boards, or threaded discussion groups. This type of Groupware primarily provides means for users to share, structure, and exchange information that typically lies outside of corporate data repositories. Other Groupware packages provide similar communication mechanisms but are more integrated with corporate data repositories and can reference the documents or experimental data within those repositories. This type of Groupware also typically provides a work environment where information is organised on a project-based structure.
Depending on the nature of the required collaboration, Groupware can be tightly integrated with existing email, resource management, scheduling, elearning, and project management systems. Given the increasing importance of collaboration both within and between organisations, Groupware systems provide selective access and information sharing.
As is the case in communities of practice, behavioural and organisational, rather than technology issues are at the forefront when encouraging the adoption and use of Groupware. The structure and goals of the shared workspace need to be defined in advance as do roles and responsibilities.
Without leadership and resource allocation the shared workspace will deteriorate into a collection of disjointed documents and unrelated information.
'There is much resistance to enter information into the official system over and above what is required.'
'Very sophisticated tools are in use in discovery, but there is a real need to improve the tools available to the rest of the company.'
Current Collaborative Practice
Collaborative solutions have reached the level of reliability, ease-of-use, and utility levels whereby they are finally beginning to change behaviour.
The tools are helping to build more effective work teams, manage globally dispersed resources, shorten development cycles and lower operating costs.
Selecting the right tool for the right task is an important feature and will result in positive collaborative experiences. Important considerations include the size of the audience, the intended level of interaction and the immediacy of the required response. Chat and instant messaging are forms of synchronous communications. Like a telephone call, a chat or instant messaging session is live and each user responds to the other in real time.
In contrast, discussion forums and email for example, are asynchronous communications. Some amount of time may pass before a person responds to a message and/or reuses, repurposes or redistributes the information. Effective collaboration requires the right mix of both synchronous and asynchronous tools used in the appropriate manner. 
Asynchronous Collaborative Tools Synchronous Collaborative Tools
There is a wide variety of collaborative tools available within pharmaceutical companies -but often these tools are being used inappropriately. In addition, many of these tools are not intuitive, which limits their wide spread adoption and use in everyday collaborative working.
Respondents reported that all too often the selection and introduction of etools failed to take into account the practical business needs of their work function. Consequently there was a mismatch between expectations and 'The mobile phone plays a key role in global collaboration by allowing people to contact other team members to share immediate thoughts.' reality. A further point raised, was that many of the tools were complicated or cumbersome to use (switching between different applications) -resulting in limited uptake. Finally implementation of new packages was more often than not poorly managed with little follow up to initial training programmes.
Unsurprisingly widespread adoption of collaborative tools has not met expectations of IT departments and top management. In contrast, a few respondents reported that their companies are now investing more time in canvassing the opinions of managers on their needs and investing heavily in implementation programmes, resulting in higher uptake.
The study examined the attitude and perceived value of current collaborative tools. Results confirmed the fact that human beings are inherently visual beings -we want to see as much as we want to hear.
Combining verbal and visual exchange of information was found to increase the "richness" and add value to the collaborative experience. 
Figure 2: Combination of Verbal and Visual Information Exchange
Audio Conferencing
Given the global acceptance of the telephone, it is no surprise that teleconferencing is the most commonly used form of conferencing in the pharmaceutical industry today. It is easy to set up and allows universal access, unlike videoconferencing there is no need to book dedicated rooms.
Teleconferencing is not without its weaknesses, however. The study revealed that the vast majority of teleconference participants multitask during audio meetings instead of focusing on the topic at hand. Some companies have introduced a "closed laptop" policy to try and combat this behaviour. Participants also complain that they do not know who is present at any given time -"people log-in and wander off." In addition, teleconferences do not allow participants to share non-verbal cues including gestures, posture and facial expressions. Therefore, despite the obvious benefits, teleconferencing is not the perfect tool.
VoIP
VoIP (voice over IP) is emerging as the second best solution to face-toface or videoconferencing. It allows for natural voice exchange and is cheaper for global organisations than meeting face-to-face or by video link.
Introducing VoIP is a significant investment but it offers long term cost effectiveness as well as collaborative benefits over and above teleconferencing -VoIP allows additional participants seamless entry into discussions avoiding the need to dial long, complicated numbers; as well as the ability to bring in other collaborative tools at any time. The move to VoIP is considered by many respondents to be a move closer in the direction of contextual collaboration.
Presence Awareness
Presence awareness, to data has been a specific functionality of instant messaging that allows people to contact each other by the ability to "see" who out of their contacts is online at any given time. It can be extended to see where contacts are and the processes they are currently involved in.
Today presence awareness is starting to move out of just instant messaging and into other systems such as VOIP, allowing the user the ability to choose the communication medium based upon the availability indicated by the presence system. 
Instant Messaging
Instant messaging provides a way to send short messages to other people in real time via pop-up messages. Initially these messages are typed, but as network bandwidth and multimedia capabilities improve, instant messaging will use voice and video. Instant messaging is one of the fastest-growing forms of Internet communications due to its real-time nature; it bridges the gap between voice calls and email. Like email it requires a response but current systems do not archive messages.
Email
Email lets users communicate with one another, coordinate activities, and easily share information. However, lack of discipline regarding the use of email leads to inappropriate and over-use, email mountains result -some respondents to the study complained of having 500+ emails on their system at any given time. Email "overload" is an underestimated problem in most pharmaceutical companies, it has a negative impact on workflow -few people have the time to deal with email, they block delete and the result is that information is lost and/or not acted upon. For this reason email has not been regarded as an effective communication tool with people preferring to use voice or even face-to-face where possible.
'Shared work spaces are revolutionising how people work.' 'Our shared workspace is just a data dump and there is no logical order to any of the informationusers know in advance that they will be unable to find anything of use in it.'
Shared Workspaces
Shared workspaces are a core of Groupware applications and provide a mechanism to share and distribute information, documents and/or objects.
The ability to share any of these with ease and immediacy is critical to meeting the expectations of joint working and to help people communicate and collaborate -shared workspaces not only provide a central information store but also access to common tools. They may also include chat rooms for real time discussions and bulletin boards to post documents or questions.
Access to the workspace can be controlled therefore promoting not only internal collaboration, but providing a means for secure collaboration with external partners.
In conjunction with other Groupware functionalities, shared workspaces: 
Data Repositories
Since their inception, Pharma companies have run experiments and recorded data. For many years that data was stored on paper or in a lab book. Converting this data into an electronic format is essential for a complete legacy system. This can be a major hurdle and probably the biggest problem associated with re-working systems is getting data "into shape" so it can easily be accessed by researchers who span the globe.
Magnifying this problem has been M&A activity, predecessor companies are often made up of predecessor companies themselves which further complicates the situation as each had their own legacy system and preferred data storage format which may or may not be compatible.
There is much debate of the value of legacy data -some feel that so much work has been done to clean up and add value to the data that it is cheaper and easier to rerun the experiment. On the other hand, others believe that there are insights into drug development in old data that are still valuablee.g. throughout the life cycle of a drug discovery programme, many insights may emerge that are relevant beyond their immediate use. However, faced with drying pipelines and the never ending quest to be more efficient in drug development, pharmaceutical companies are beginning to tackle the technical and cultural issues of what to do with legacy data. Keeping track of all the information generated in the drug development process and exploiting it to the full is far from straightforward. Much potentially useful information continues to be lost because it never gets further than an individual's brain.
The challenges over successful data mining all centre around integrationintegration of access, integration of mining tools, integration of interpretation tools, etc. At the moment, information still tends to be fragmented and sit in "silos." And, more importantly, the study highlights the fact that the sharing of information and knowledge has not been high priority. Companies often maintain large data sets which can be physically accessed but which lack the "metadata." Metadata is especially important to legacy data because the context is lost over time. Therefore, to create knowledge from existing information companies today have to make sure that the data they are storing will be of use to future scientists -systems must be designed that capture both data and the context of the experiment An outstanding issue is that many researchers have difficulty dealing with the huge amount of information available and many are still spending too much time accessing irrelevant information. Even when new information is processed, there are few effective ways to disperse any new knowledge that is created. Portals are providing a partial solution by allowing user defined functionality and role based access, yet there remains an unmet need for search tools to be more intuitive and for users to be able to effectively "profile" the information they want to see. Searching is time consuming and relies on proactive user pull. Respondents commented that they need a more intelligent system that allows them to pre-define the information they require and one that automatically links them to critical internal and external information based on this profile.
Electronic Lab Notebooks
Electronic lab notebooks are essentially data repository systems designed to support user workflow and processes through the discovery cycle. In practical terms this means being able to document accurately experiments that have been carried out as well as search for, retrieve and analyse those experiments in order to inform future research efforts -the key point being that digitised information is far easier to share and collaborate on.
The research community has mixed emotions regarding the adoption of elab notebooks. There are those who believe that their paper lab books are as personal as diaries and who are unwilling to make that information available to a wider audience; and then there are others who are eager to 'Companywide portals are expected to change working processesportals will provide single access for all user needs.' gain from the potential benefits of this tool: Investment in e-lab notebooks will provide pharmaceutical companies with the answer to an unavoidable need; namely that information storage, sharing and retrieval affords a core competitive strength, but widespread uptake of the tool will require attention to the more soft issues of human behaviour. Widespread adoption of e-lab notebooks will require a change in attitude and behaviour. Users must realise a net gain from the system thus aiding not only uptake but also reducing resistance to change.
Portals
Portals are creating new channels for information and data access from a single entry point. Single entry is becoming an important feature as users find the process of having to go into different systems and enter multiple passwords not only irritating, but time consuming.
Portals serve as a 'one-stop' information resource for specific topics on an intranet and facilitate the link between cross-organisational communities.
The study revealed increased deployment of the portal model for therapy groups, product teams and functional departments.
The content and presentation of the default page presented upon access can be customised towards specific user communities or groups -users can enter and immediately gain access to the tools they require and see what is important, read it and/or download it. In an era where access to vast amounts of data is possible, portals provide a means of pulling all the relevant information for specific user groups together in one space so that it can be accessed and mined.
'If you want to find someone, you ring around.'
'The efficiency of net meetings could be increased if documents for discussion were sent out in advance.'
Expertise Locators
For knowledge to be effectively created, connections must be made -not only between information and people, but connections between the people themselves.
The study highlighted that common questions are, "How do I identify people in my organization who have the expertise I need to learn about;
and how do we share knowledge person-to-person?" Solutions to these questions have been implemented to varying degrees across the industry with many companies placing little emphasis in this area.
Online phone books are often available where people are listed under title and department leaving it to a best guess scenario as to who to contact.
Departmental websites may provide contact details, but many people still rely heavily on existing social networks. The problem is that social networks are often broken following merger. Some companies have introduced more formalised "expertise locators" which store information on people's competences and experiences.
Ideally, when storing data in central repositories, the metadata should provide a link from finding the information to contacting the people involved in its creation. Similarly having found a person, respondents commented that it should be possible to find the work they have primed as author or contributed to. Search navigation needs to be able to switch from information based navigation to people and vice-versa.
Net Meetings
A network meeting application allows users to hold meetings over the network. Attendees sit at their workstations and collaborate on a joint project by opening documents on the screen and working on these documents together. Electronic mediated communication such as this lacks the interpersonal cues that are so important for building trust between team members. Participation among new members may be difficult without visual interaction. Introduction prior to these meetings helps build relationships among participants. Respondents to the study commented that information does not flow freely unless there is mutual trust between all attendees. As with teleconferencing, it is preferable for photos of team members to be distributed to help participants visualise real people.
The rapid growth in net meetings is due to the fact that users need only an Internet-connected computer and a telephone, both of which are available on virtually every desktop. The downside to net meetings is that there is no 'Videoconferences are a good way of putting faces to names as getting everyone together faceto-face is not often possible.' visual link, but the convenience and immediacy of the tool often outweighs the need for visual cues. Where visual links are required, network meetings are run in conjunction with videoconference sessions so attendees can see one another and collaborate on computers at the same time. In fact, many study respondents often expect a net meeting to run concurrently with a videoconference not only to add value to the video link but to allow additional non-visual attendance.
Net meetings in conjunction with videoconferences are particularly useful in training situations, where new data has to be presented to teams, or in situations that require decision making. In large meetings, respondents found it is useful to have a chat window open. This helps where language may be a barrier for some participants -due to their poor English skills they may be hesitant to ask questions out loud, a dialog box gives these people the time to compose the question before it is posted.
Videoconferencing
Where audio conferencing fails, videoconferencing excels by allowing participants to share both verbal and non-verbal cues. By allowing people not only to hear but also to see other participants, videoconferencing enables more effective communications and fosters and environment of interaction and collaboration. In addition, visual cues allow foreign language speakers to be better understood. A particularly important issue is that participants on-camera cannot easily multitask, leave the room, or be distracted; which further enhances the overall impact of the meeting.
The ideal videoconference situation remains high-interaction meetings between a relatively small group of participants or locations -multiple screens (>4) often diminishes the overall quality of the interaction.
However, collaboration is more effective if the attendees have met face-toface before -people tend to trust others more if they have already met and built a personal relationship; and teams that have established mutual trust, communicate and exchange information more readily and openly.
Although videoconferencing is an excellent vehicle for bringing globally dispersed teams together, it is far from a perfect tool. Imperfect visual images plus time delays lead to misinterpretation of verbal communication and body language. Technology is already in place that affords "movie quality" pictures, but videoconferencing is inherently expensive, hence high quality systems are not widely available.
Co-ordinating access to videoconference suites across multiple locations is also a cumbersome task -many rooms are booked well in advance. In addition, even with dedicated administrators, time is lost in set up and getting everyone ready to start. For many, today's videoconferencing experience offers little value over and above teleconferences and/or net meetings.
To make videoconferencing appeal to a wider audience it has to be cheaper as well as more accessible, reliable, and faster to set up. Many respondents to the study were concerned that desktop video chat would be greedy in terms of bandwidth and if general access were allowed then network performance could be seriously compromised. In response to the accessibility issue, a small number of companies are piloting video kiosks which offer wide potential across organisations:
• Human resources: global interviewing and recruitment • Discovery labs: viewing samples and discussing projects
• Senior executives: strategy and operations meetings
Face-to-Face
Technical tools cannot substitute the traditional human face-to-face way of collaborating and sharing information around a table -"nothing beats seeing the whites of their eyes." It is the best way of building relationships and team moral. Face-to-face affords the full range of visual cues without any misinterpretation. Nevertheless, wide geographical distribution of teams means that routine face-to-face is not possible due to cost of travel and time constraints of participants. Even co-located workers often resort to teleconferencing rather than attempting to get multiple people together in the same room at the same time.
The goal of future of collaborative environments is to simulate "face-toface" working as closely as possible by affording seamless transfer between different modes of communication and collaboration.
Summary of Attitudes to Current Collaborative Tools
The following tables summarise respondent views to current tools and practices.
'Technology must be simple to win acceptance quickly.' 
Winning Strategies for Better Future Collaboration
Select the Right Technological Collaborative Environment
Selecting the optimal collaboration tool to fit the situation is a critical consideration.
'The most important factor is to keep the technology straightforward and intuitive so that it is easy for people to learn and to use -that way they keep using it.' 'All too often the technology is too complicated to use.' In selecting the appropriate conferencing tool, users must consider the nature of their requirements and the potential benefits (and weaknesses) of their conferencing options. The most important considerations are the size of the audience and the intended level of interaction. As above, the right choice might include a combination of options. For example, a quarterly commercial team meeting might include a videoconference between 3 or 4 locations, a teleconference to permit remote users to participate and a live net meeting session. 
Ensure Collaboration is Contextual -intuitive and seamless
Since the 1990s, collaboration strategies have revolved around tools with little attention being paid to user needs and behaviour.
Email, group calendars, and discussion forums are representative of firstgeneration solutions for individual and team activity. Instant messaging, web conferencing, and Groupware represent second generation tools being deployed. However, simply giving users the perfect tool for each situation is not always the correct strategy. Not only does the unchecked proliferation of tools for each situation result in higher levels of IT complexity (and costs), but individual productivity gains without impact on process outcomes are unlikely to impact on the bottom line.
Earlier collaborative efforts focused on people; today the focus is on how people work within processes -it is no longer a personal productivity endeavour (e.g. saving time or making individual tasks more efficient), the goal now is to enable processes to perform at a higher level.
Contextual collaboration carries with it several attributes and features.
Tools currently used for collaboration typically require the user to switch from among several open windows in order to communicate with team members or colleagues -this can be both cumbersome and frustrating.
Contextual collaboration represents an integration of tools into a unified
interface -tools such as word processors, instant messaging, shared calendars, Groupware, presence and real-time capabilities would all be integrated so that teams could communicate quickly and instantly from a single environment. The integrated environment provides a managed repository providing document and record management and an audit trail.
Without permanent management of the information throughout its lifecycle it rapidly loses value no matter how rich the collaborative environment. The goal of contextual collaboration is to make online collaboration as simple and as intuitive as possible allowing more proactive goal management and more focused work processes. It mimics the richness of co-located small team working by combining process rigour for compliance with captured ad hoc interaction and collaboration. The movement towards contextual collaboration continues to be adopted to improve productivity, reduce coordination costs, and better connect people to peers and teams.
Create the Culture
Not only do pharmaceutical companies have to ensure that the technology is intuitive and seamless, but they need to develop and reward a culture of openness and sharing. Shifting a corporate culture from being competitive to being co-operative is no small undertaking and will require changes at all levels of the organisation, including the CEO.
Training is required -users must be familiar with and comfortable using the tools. If they lack confidence in their abilities, they won't adopt. When a collaborative solution is first adopted, the structure of the workspace is only an approximation of user best practice, no matter how intimately involved the users were in defining the environment. Over time as end-user confidence and familiarity evolves, the sophistication of the workspace will grow accordingly. With adequate training and support, the result will be a constant cycle of positive reinforcement and continuous enhancements in productivity.
Employees need to be given incentives to contribute to the system; rewards could be either financial or psychological (e.g. peer recognition).
Users must realise a net gain from the system and the value of sharing information through collaboration must be reinforced. A major failing is that the majority of pharmaceutical companies do not yet reward or include collaboration in personal objectives -and without incentives behaviour will not change.
Measure the Impact
Collaborative tools are likely to be adopted more widely within pharmaceutical companies and their use become more routine if employees and executives understand how much time and money can be saved -and savings can be dramatic.
For example, at some companies, collaborative technologies have reduced The example below is based on the most obvious hard benefit from collaborative solutions in the pharmaceutical industry i.e. that of travel reduction; it is indicative only and based on comments and opinions gathered during the interview process. The direct expenses of salary, flights, sundries and hotels are included. From the simple example above it can be concluded that by avoiding 3 to 4 people the need to travel and meet face-to-face once a month over the clinical development period; the savings in terms of man hours are greater than one year, and that the cost savings equate to those of a toxicology or small formulation study for example.
A growing trend in the pharmaceutical industry is the growing reliance on external partners. With margins to preserve and resources to optimise, companies today must shed "non-core" activities. The second example relates to productivity increases in clinical development as a result of improved collaboration with external partners. In the past, documents were shared with external CROs using fax and/or courier. Now, shared workspaces are created and teams from both sides are working in real time on information -avoiding delays can reap significant cost savings in addition to decreasing cycle times.
'Improved, better, and quicker decisions would prevent project hold ups.' 
Results from varying levels of productivity improvement Benefits
Assumption: that collaborative tools support strategic alliances with external partners. The result of teams from both sides working in real time can offer significant productivity gains The third example relates to productivity increases in discovery as a result of easier access to relevant information and sources of expertise. In many companies, researchers are spending more than 15% of their time searching for data and information, 7 this leads to bad and slow decision making. High-tech, cutting-edge drug discovery programmes are all very well but bottlenecks at the data processing stage often negate the potential advantages of new technology. 
Assumption: that collaborative tools result in productivity improvements in discovery as a result of easier access to relevant information and expertise
Considering that the implementation of collaborative tools to support knowledge creation and management has the potential to increase research productivity by at least 5%, 4 then on average 3.3 months and US$9.9 million could be saved in the discovery process.
Promote the Benefits to Improve Adoption
The bottom line is that effective collaboration strategies will enable individuals and teams to be more productive within processes, with success measured via improvement in process outcomes and more sustained levels of innovation resulting from company insight.
New collaborative and communications tools deliver productivity improvements as both hard, quantifiable benefits (already discussed), and 
Conclusions
Collaborative solutions now represent a core business tool that global pharmaceutical companies need to fully embrace in order to compete in today's global marketplace.
The major finding of the study was that successful implementation of collaborative working solutions requires intuitive tools combined with the right cultural environment. Simplicity -tools developed for large groups of people must be easy to learn as well as simple, intuitive and traightforward to use Accessibility -tools must fit seamlessly within the desktop environment Customisation -different groups have different needs, tools hould be customisable as well as facilitate the customised access to information Integration -tools ideally need to be in an integrated and nked family that enables a user to move seamlessly from one tool to the next (contextual collaboration)
Relevance -the tools must be relevant to the context of work as well as to meet specific business objectives
Connectivity -easy access to everyone else
Reliability -tools must work in the manner expected and ystems must be maintained
Critical Success Factors for Creating a Collaborative Environment Critical Success Factors for Tools
•A corporate culture of openness and sharing •Rewards for demonstrating effective team working and collaborative behaviour •Appropriate and timely training to support introduction of new tools •Leadership and example -team leaders must provide authority on collaborative behaviour •Resource must be allocated -both in terms of technical support and system maintenance, but also at team level to direct the use and continuous optimisation of the collaborative workspace •Defined roles and responsibilities -at all levels from the implementation team down to the project teams themselves •The impact of collaboration needs to be measured whilst at the same time promoting the benefits Simplicity -tools developed for large groups of people must be easy to learn as well as simple, intuitive and traightforward to use Accessibility -tools must fit seamlessly within the desktop environment Customisation -different groups have different needs, tools hould be customisable as well as facilitate the customised access to information Integration -tools ideally need to be in an integrated and nked family that enables a user to move seamlessly from one tool to the next (contextual collaboration)
Connectivity -easy access to everyone else
Reliability -tools must work in the manner expected and ystems must be maintained 
Critical Success Factors for Creating a Collaborative Environment
Critical Success Factors for Tools
New tools and communication infrastructures are now on the horizon which will enable true contextual collaboration. With the convergence of voice, video, and data networks, more pharmaceutical companies will realise increased value through deploying IP collaborative solutions -including IP telephony (VoIP), unified messaging, voice mail, and audio, video, and web conferencing. These personal tools will enable workers to communicate anywhere, anytime, with local and remote colleagues, without leaving the comfort and efficiency of their workspace. Individuals will be able to work with live information that is relevant, current and fluid. Online collaboration will be as simple and as intuitive as it is to work with people in the same room.
However, to truly embed collaborative working behaviour requires a fundamental change in everyday working practice -to succeed the benefits of collaboration and knowledge sharing must be continually reinforced. A successful collaborative framework is a driver for cultural change and is a vehicle for pharmaceutical companies to realise the full potential of their greatest asset -their people. 
Endnote
We would like to extend our thanks to all the respondents for their time and valuable inputs to this review. 
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